Viking Therapeutics Inc. (VKTX) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Comparison side by side

Viking Therapeutics Inc. (NASDAQ:VKTX) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation of the two firms.

Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics Inc. N/A 0.00 20.91M -0.45 0.00 Galmed Pharmaceuticals Ltd. 2.31M 70.86 9.79M -0.67 0.00 Table 1 showcases the gross revenue, earnings per share and valuation of Viking Therapeutics Inc. and Galmed Pharmaceuticals Ltd.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies. Net Margins Return on Equity Return on Assets Viking Therapeutics Inc. 0.00% -15.8% -15.1% Galmed Pharmaceuticals Ltd. -423.81% -18.6% -17.5% Volatility and Risk

Viking Therapeutics Inc. is 189.00% more volatile than Standard & Poor’s 500 due to its 2.89 beta. In other hand, Galmed Pharmaceuticals Ltd. has beta of 2.87 which is 187.00% more volatile than Standard & Poor’s 500.


Viking Therapeutics Inc.’s Current Ratio is 64.6 while its Quick Ratio is 64.6. On the competitive side is, Galmed Pharmaceuticals Ltd. which has a 43.3 Current Ratio and a 43.3 Quick Ratio. Viking Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Galmed Pharmaceuticals Ltd.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Viking Therapeutics Inc. and Galmed Pharmaceuticals Ltd. Sell Ratings Hold Ratings Buy Ratings Rating Score Viking Therapeutics Inc. has a consensus target price of $29, and a 262.95% upside potential. Competitively the consensus target price of Galmed Pharmaceuticals Ltd. is $28, which is potential 258.97% upside. Based on the data shown earlier, Viking Therapeutics Inc. is looking more favorable than Galmed Pharmaceuticals Ltd., analysts belief.

Institutional and Insider Ownership

The shares of both Viking Therapeutics Inc. and Galmed Pharmaceuticals Ltd. are owned by institutional investors at 61.8% and 38.2% respectively. About 8.7% of Viking Therapeutics Inc.’s share are held by insiders. Comparatively, Galmed Pharmaceuticals Ltd. has 21.61% of it’s share held by insiders.


Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Viking Therapeutics Inc. -16.21% -32.62% -17.24% -10.92% 155.68% 133% Galmed Pharmaceuticals Ltd. -2.33% -18.58% -36.59% 19.57% 3.33% -8.52% For the past year Viking Therapeutics Inc. has 133% stronger performance while Galmed Pharmaceuticals Ltd. has -8.52% weaker performance.


Viking Therapeutics Inc. beats on 7 of the 10 factors Galmed Pharmaceuticals Ltd.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder. In addition, it develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.


Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *